Skip to main content

Table 2 Changes in variables

From: Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study

 

Canagliflozin

Teneligliptin

Baseline

24 weeks

p

Baseline

24 weeks

p

HbA1c (%), mean ± SD

7.7 ± 0.6

7.0 ± 0.6

< 0.0001

7.8 ± 0.8

7.2 ± 0.7

 < 0.0001

HOMA-IR, mean ± SD

4.9 ± 6.1

3.5 ± 6.4

< 0.0001

4.0 ± 3.6

3.7 ± 2.8

0.2451

Ketone body (µmol/L), mean ± SD

110.0 ± 113.8

206.4 ± 186.3

< 0.0001

110.2 ± 94

109.8 ± 80.3

0.7946

Body weight (kg), mean ± SD

79.0 ± 15.2

76.6 ± 15.2

< 0.0001

79.2 ± 16.7

79.1 ± 16.4

0.0899

Ht (%), mean ± SD

44.6 ± 3.5

47.2 ± 3.5

< 0.0001

44.9 ± 4.0

44.9 ± 4.3

0.7740

Energy intake (kcal/day), mean ± SD

1747.7 ± 634.3

1859.7 ± 639.8

0.0872

1789 ± 601.7

1620.9 ± 516.9

0.0354

Protein intake (g/day), mean ± SD

66.1 ± 26.9

69.9 ± 29.1

0.1032

67.8 ± 28.4

64.3 ± 26.1

0.2634

Fat intake (g/day), mean ± SD

50.1 ± 18.4

53.1 ± 19.0

0.1355

54.4 ± 23.2

47.9 ± 19.3

0.0105

Carbohydrate intake (g/day), mean ± SD

216 ± 73.2

236.5 ± 83.8

0.1072

230.1 ± 90.8

209.7 ± 75.8

0.1632

Sucrose intake (g/day), mean ± SD

7.8 ± 6.2

8.7 ± 6.6

0.0889

9.0 ± 7.4

8.3 ± 6.0

0.8843

AST (IU/L), mean ± SD

32.1 ± 19.7

25.5 ± 12.0

< 0.0001

30.3 ± 17.7

30.6 ± 20.5

0.9764

ALT (IU/L), mean ± SD

40.4 ± 28.0

30.1 ± 19.6

< 0.0001

41.1 ± 33.1

40.4 ± 36.0

0.4180

γ-GTP (IU/L), mean ± SD

67.6 ± 96.9

47.4 ± 43.9

< 0.0001

54.3 ± 52.6

51.8 ± 51.3

0.2547

Fib 4 index, mean ± SD

1.3 ± 0.8

1.2 ± 0.6

0.1047

1.2 ± 0.6

1.2 ± 0.7

0.2362

  1. AST aspartate transaminase, ALT alanine aminotransferase, FIB4 index fibrosis-4 index, γ-GTP γ-glutamyl transpeptidase, HOMA-IR homeostasis model assessment of insulin resistance